Mayeen NF, Salma U, Abu Kasim NH, Mahmoud O, Haque N. Hurdles to overcome for mesenchymal stem cell translation from bench to bedside. World J Stem Cells 2025; 17(12): 114349 [DOI: 10.4252/wjsc.v17.i12.114349]
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Dec 26, 2025 (publication date) through Jan 1, 2026
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Stem Cells
ISSN
1948-0210
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Mayeen NF, Salma U, Abu Kasim NH, Mahmoud O, Haque N. Hurdles to overcome for mesenchymal stem cell translation from bench to bedside. World J Stem Cells 2025; 17(12): 114349 [DOI: 10.4252/wjsc.v17.i12.114349]
Noor Hayaty Abu Kasim, Department of Restorative Dentistry, University of Malaya, Kuala Lumpur 50603, Malaysia
Okba Mahmoud, Department of Clinical Science, Ajman University, Ajman 346, United Arab Emirates
Nazmul Haque, Department of Regenerative Medicine, Concord Stem Cell Limited, Dhaka 1209, Bangladesh
Co-first authors: Naiyareen Fareeza Mayeen and Umme Salma.
Author contributions: Mayeen NF and Salma U contributed equally to this manuscript and are co-first authors. Mayeen NF and Salma U drafted and wrote the article; Haque N contributed to the conception and design of the study; Abu Kasim NH, Mahmoud O, and Haque N contributed to the manuscript writing, and made critical revisions related to the relevant intellectual content of the manuscript; and all the authors have approved the final version of the article.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Received: September 17, 2025 Revised: October 20, 2025 Accepted: November 21, 2025 Published online: December 26, 2025 Processing time: 99 Days and 17.2 Hours
Core Tip
Core Tip: Regenerative medicine has been practiced in a variety of settings for decades. It is a multidisciplinary branch of medicine that aims at replacing degenerated cells or regenerating new human cells, tissues, or organs that have been lost or damaged due to the effects of aging, illness, or congenital defects. The main objective of regenerative medicines is to restore normal functions of the cells or tissues in patients affected by degenerative disorders. Mesenchymal stem cells (MSCs) have the potential to cure the most critical regions or take over the function of a wounded organ that is considered beyond repair using conventional therapies. In the last two decades, thousands of in vitro, in vivo, and clinical trials have been conducted using MSCs. Though the regenerative potential of MSCs has been extensively studied, there are still a lot of challenges that need to be addressed for their successful translation from bench to bedside.
